AI assistant
NEOGENOMICS INC — Director's Dealing 2022
Mar 4, 2022
32227_dirs_2022-03-03_382f1117-775b-42b4-a74b-cdd405b47f52.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: NEOGENOMICS INC (NEO)
CIK: 0001077183
Period of Report: 2022-03-01
Reporting Person: Wallar Gina M (President, Pharma Services)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-03-01 | Common Stock | A | 11677 | — | Acquired | 33443 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-03-01 | Stock Option (Right to Buy) | $21.41 | A | 28506 | Acquired | 2029-03-01 | Common Stock (28506.0) | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $9.22 | 2023-04-19 | Common Stock (6667.0) | 6667 | Direct |
| Stock Option (Right to Buy) | $13.87 | 2023-12-12 | Common Stock (8334.0) | 8334 | Direct |
| Stock Option (Right to Buy) | $20.83 | 2026-05-01 | Common Stock (7153.0) | 7153 | Direct |
| Stock Option (Right to Buy) | $27.34 | 2027-05-01 | Common Stock (7879.0) | 7879 | Direct |
| Stock Option (Right to Buy) | $48.99 | 2028-05-01 | Common Stock (8595.0) | 8595 | Direct |
| Stock Option (Right to Buy) | $43.95 | 2028-07-05 | Common Stock (10126.0) | 10126 | Direct |
Footnotes
F1: On March 1, 2022, Ms. Wallar was granted 11,677 restricted stock awards. These awards vest ratably over the first four anniversary dates of the grant date.
F2: This balance includes 104 shares that were acquired at a price of $19.16 per share pursuant to NeoGenomics's Employee Stock Purchase Plan (ESPP) during the month ended January 31, 2022. The shares wereacquired in transactions exempt from Section 16b-3.
F3: On April 19, 2018, Ms. Wallar was granted 20,000 stock options. The options vested ratably over the first three anniversary dates of the grant date.
F4: On December 12, 2018, Ms. Wallar was granted 25,000 stock options. The options vested ratably over the first three anniversary dates of the grant date.
F5: On May 1, 2019, Ms. Wallar was granted 9,537 stock options. The options vest ratably over the first four anniversary dates of the grant date.
F6: On May 1, 2020, Ms. Wallar was granted 7,879 stock options. The options vest ratably over the first four anniversary dates of the grant date.
F7: On May 1, 2021, Ms. Wallar was granted 8,595 stock options. The options vest ratably over the first four anniversary dates of the grant date.
F8: On July 5, 2021, Ms. Wallar was granted 10,126 stock options. The options vest ratably over the first four anniversary dates of the grant date.
F9: On March 1, 2022, Ms. Wallar was granted 28,506 stock options. These options vest ratably over the first four anniversary dates of the grant date.